University Hospitals Sussex NHS Foundation Trust, Brighton, UK
University Hospitals Sussex NHS Foundation Trust, Brighton, UK.
Clin Med (Lond). 2022 May;22(3):225-229. doi: 10.7861/clinmed.2022-0150.
Lymphocytosis is a common blood-test finding. Establishing whether the cause of lymphocytosis is benign or malignant is key to managing patients appropriately. A lymphocytosis should always prompt clinical review including a thorough history, examination and appropriate preliminary investigations (blood tests, blood film). The majority of patients with chronic lymphocytic leukaemia (CLL) present incidentally due to a lymphocytosis found on routine blood tests. Patient outcomes vary considerably based on genetic pre-disposition and various prognostic markers (age, Binet or Rai staging, and B2-microglobulin). Although not curative, chemo-immunotherapy is an effective treatment strategy for the majority of CLL patients with progressive disease. More recently, novel oral therapies have been developed that target key signalling and apoptosis pathways and that are being used in relapse settings and as first-line treatments for certain patients.
淋巴细胞增多是一种常见的血液检测结果。确定淋巴细胞增多的原因是良性还是恶性对于患者的恰当管理至关重要。淋巴细胞增多症应始终提示进行临床检查,包括详细的病史、体格检查和适当的初步检查(血液检查、血涂片)。大多数慢性淋巴细胞白血病(CLL)患者因常规血液检查发现淋巴细胞增多而偶然发现。患者的预后因遗传易感性和各种预后标志物(年龄、Binet 或 Rai 分期和β2-微球蛋白)而异。尽管不能治愈,但化疗免疫疗法是大多数进展性疾病的 CLL 患者的有效治疗策略。最近,开发了针对关键信号和凋亡途径的新型口服疗法,这些疗法在复发时使用,并作为某些患者的一线治疗。